北芯生命募10亿首日涨183% 累计未弥补亏损6.86亿元

Core Viewpoint - North Chip Life Technology Co., Ltd. (stock code: 688712.SH) has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with a closing price of 49.64 yuan, representing a 183.33% increase, and a total market capitalization of 20.7 billion yuan [1]. Company Overview - North Chip Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, with 17 approved and in-development products as of September 30, 2025 [1]. - The company aims to provide transformative solutions for cardiovascular disease diagnosis and treatment, covering five major product categories including IVUS and FFR systems [1]. Financial Performance - The company reported a cumulative loss of 686.41 million yuan as of June 30, 2025, indicating potential challenges in future cash dividends [2]. - From 2022 to 2024, the company experienced a total net loss of 473.40 million yuan, with revenues increasing from 92.45 million yuan in 2022 to 316.60 million yuan in 2024 [8][9]. Shareholding Structure - The company has no controlling shareholder, with the actual controller being Song Liang, who holds 16.15% of the shares directly and has significant influence over company decisions [2][3]. - Other shareholders are primarily financial investors who do not seek control of the company, supporting Song Liang's position as the actual controller [3]. Fundraising and Use of Proceeds - North Chip Life raised a total of 998.64 million yuan in its IPO, with a net amount of 898.89 million yuan after deducting issuance costs [5]. - The funds will be allocated to the construction of an interventional medical device industrialization base, R&D projects, and to supplement working capital, with a total planned investment of 952.21 million yuan [6][7]. Future Projections - For 2025, the company expects revenue between 520 million yuan and 560 million yuan, representing a growth of 64.24% to 76.88% year-over-year, and a net profit of 78 million yuan to 88 million yuan, indicating a growth of 278.91% to 301.85% [13].